LAM point-of-care TB testing reduces mortality in people with HIV/TB co-infection in hospital

Lesley Odendal

All-cause 8-week mortality is reduced by rapid point-of-care urine-based testing for tuberculosis (TB), using a test for detection of mycobacterial lipoarabinomannan (LAM) to guide rapid treatment initiation in hospitalised HIV-positive people with signs and symptoms of TB, according to a late-breaker study presented by Dr Jonny Peter of the University of Cape Town, and colleagues, at the 46th Union World Conference on Lung Health in Cape Town from 2 to 6 December 2015.

Those who received LAM testing in addition to standard of care diagnostics were 18% less likely to die at 8 weeks (aHR = 0.82; 95% CI: 0.70-0.96, p = 0.015).

The LAM strip test measures for the presence of lipoarabinomannan in urine. The test has shown variable sensitivity and specificity in different populations, and has performed best in studies of hospitalised patients with HIV infection and advanced immunosuppression (CD4 count below 150 cells/mm3). The test is not considered suitable for outpatient screening. (Lawn 2012)

Speeding up diagnosis by using a point-of-care test in addition to laboratory diagnostic tests such as TB culture or Xpert MTB/RIF has the potential to speed up the initiation of treatment and to increase the number of people receiving treatment.

The randomised controlled trial studied whether the LAM strip test, in combination with current available TB diagnostics, would improve TB-related mortality, morbidity and length of hospital stay in HIV-positive people. TB mortality is high, especially in people living with HIV with extensive immune damage, where a TB diagnosis is already difficult.

The study was conducted in South Africa, Tanzania, Zambia and Zimbabwe.

January 12, 2016
Year of publication
Resource types
Conference materials, Journal and research articles
rapid point-of-care testing, tuberculosis, HIV, TB, HIV-TB co-infection, testing, mycobacterial lipoarabinomannan (LAM), treatment initiation, 46th Union World Conference on Lung Health, LAM testing, urine-based testing, advanced immunosuppression, in-hospital patients, early diagnosis, reduced mortality, treatment

Similar Resources

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on vulnerable populations, including TB in prisons and intimate partner violence in the context of HIV.

This issue of the Southern African HIV Clinicians Society's "HIV Nursing Matters" online magazine focuses on key populations.

At the 44th World Health Assembly in 1991, the burgeoning, and now modern day, tuberculosis pandemic was brought to the world's attention, reporting that 6 million new tuberculosis cases and 3 million associated deaths were occurring worldwide each year.

Prisoners and detainees worldwide have higher burdens of HIV, viral hepatitis, and tuberculosis than the communities from which they come. This disease burden among prisoners has been recognised since the early years of these inter-related pandemics.

HIV pre-exposure prophylaxis (PrEP) is becoming a pivotal strategy for HIV prevention. Understanding the impact of risk factors for HIV transmission to identify those at highest risk would favour the implementation of PrEP, currently limited by costs.

Rapid diagnostic tests (RDTs) account for more than two-thirds of malaria diagnoses in Africa. Deletions of the Plasmodium falciparum hrp2 (pfhrp2) gene cause false-negative RDT results and have never been investigated on a national level.

Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline.

A six-month course of isoniazid preventive treatment (IPT) at the beginning of the Temprano trial in Ivory Coast reduced the risk of death by 37% over a mean follow-up period of 4.5 years, Anani Badje reported at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle…

Infants exposed to an antiretroviral regimen of tenofovir, emtricitabine and efavirenz (Atripla) from conception experienced fewer adverse birth outcomes compared to other three-drug regimens, according to a study of births in Botswana between 2014 and 2016, presented on Tuesday at the …